SUN Pharmaceutical Industries Limited — Celecoxib Exporter Profile
Indian Pharmaceutical Exporter · #11 for Celecoxib · $2.8M export value · DGFT Verified
SUN Pharmaceutical Industries Limited is the #11 Indian exporter of Celecoxib with $2.8M in export value and 127 verified shipments. SUN Pharmaceutical Industries Limited holds a 2.1% market share in Celecoxib exports across 9 countries. The company exports 118 pharmaceutical products worth $979.8M across 25 therapeutic categories.
SUN Pharmaceutical Industries Limited — Celecoxib Export Profile: Buyers & Destinations
Where Does SUN Pharmaceutical Industries Limited Export Celecoxib?
| Country | Value | Shipments | Share |
|---|---|---|---|
| SOUTH AFRICA | $722.8K | 31 | 29.2% |
| BRAZIL | $466.1K | 27 | 18.8% |
| FRANCE | $353.9K | 25 | 14.3% |
| BELGIUM | $290.2K | 19 | 11.7% |
| THAILAND | $203.5K | 11 | 8.2% |
| OMAN | $201.6K | 5 | 8.2% |
| ECUADOR | $141.4K | 4 | 5.7% |
| NIGERIA | $52.4K | 9 | 2.1% |
| UKRAINE | $40.8K | 4 | 1.7% |
SUN Pharmaceutical Industries Limited exports Celecoxib to 9 countries. The largest destination is SOUTH AFRICA accounting for 29.2% of SUN Pharmaceutical Industries Limited's Celecoxib shipments, followed by BRAZIL (18.8%) and FRANCE (14.3%). These destinations reflect SUN Pharmaceutical Industries Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Celecoxib from SUN Pharmaceutical Industries Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| M/S. RANBAXY PHARMACETICALS PTY LTD | SOUTH AFRICA | $279.2K | 8 |
| M/S. RANBAXY FARMACEUTICA LTDA : | BRAZIL | $252.3K | 15 |
| YUSEN LOGISTICS BENELUX BELGIUM | BELGIUM | $235.1K | 14 |
| M/S. PLANET PHARMA | FRANCE | $203.8K | 17 |
| M/S. RANBAXY PHARMACEUTICALS PTY(LT | SOUTH AFRICA | $133.8K | 5 |
| M S RANBAXY PHARMACEUTICALS PTY LIMITED | SOUTH AFRICA | $123.3K | 6 |
| M/S. DYVENPRO DISTRIBUCION Y VENTA | ECUADOR | $110.1K | 3 |
| MS PLANET PHARMA | FRANCE | $87.6K | 3 |
| MS RANBAXY FARMACEUTICA LIMITED | BRAZIL | $80.8K | 4 |
| NATIONAL PHARMACEUTICAL INDUSTRIES | OMAN | $73.1K | 2 |
SUN Pharmaceutical Industries Limited supplies Celecoxib to 45 buyers globally. The largest buyer is M/S. RANBAXY PHARMACETICALS PTY LTD (SOUTH AFRICA), followed by M/S. RANBAXY FARMACEUTICA LTDA : (BRAZIL) and YUSEN LOGISTICS BENELUX BELGIUM (BELGIUM). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Celecoxib Export Value and How Much Does SUN Pharmaceutical Industries Limited Contribute?
India exported $62.9M worth of Celecoxib through 4,880 shipments from 326 suppliers to 112 countries, serving 781 buyers globally. SUN Pharmaceutical Industries Limited contributes $2.8M to this total, accounting for 2.1% of India's Celecoxib exports. SUN Pharmaceutical Industries Limited ships Celecoxib to 9 countries through 45 buyers.
What Is the Average Shipment Value for SUN Pharmaceutical Industries Limited's Celecoxib Exports?
SUN Pharmaceutical Industries Limited's average Celecoxib shipment value is $22.0K per consignment, based on 127 shipments totaling $2.8M. The largest destination is SOUTH AFRICA (29.2% of SUN Pharmaceutical Industries Limited's Celecoxib exports).
How Does SUN Pharmaceutical Industries Limited Compare to Other Indian Celecoxib Exporters?
SUN Pharmaceutical Industries Limited ranks #11 among 326 Indian Celecoxib exporters with a 2.1% market share. The top 3 exporters are ALEMBIC PHARMACEUTICALS LIMITED ($12.2M), CIPLA LIMITED ($12.2M), MACLEODS PHARMACEUTICALS LTD ($9.2M). SUN Pharmaceutical Industries Limited processed 127 shipments to 9 destination countries.
What Celecoxib Formulations Does SUN Pharmaceutical Industries Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CELECOXIB CAP 200MG 10S BRAZ PACK:10s ST | $122.5K | 4 |
| COLCIBRA CAP 200MG(CELECOXIB CAPSULES 20 | $120.9K | 3 |
| COLCIBRA CAP 200MG (CELECOXIB CAPSULES 2 | $100.0K | 2 |
| COLCIBRA CAP 100MG(CELECOXIB CAPSULES 10 | $87.2K | 2 |
| COLCIBRA CAP 200MG PACK:BOX3X10S BATCH:DFE7087A EACH CAP CONTS.CELECOXIB 200MG | $78.5K | 5 |
| COLCIBRA CAP 200MG PACK:BOX3X10S BATCH:DFF0314A EACH CAP CONTS.CELECOXIB 200MGPCS | $73.0K | 2 |
| COLCIBRA CAP 200MG(CELECOXIB CAPSULES 200MG)PACK:BOX3X10S BATCH:DFE7748A, DFE7749DPCS | $63.7K | 3 |
| COLCIBRA CAP 200MGCELECOXIB CAPSULES 200MGPACK:BOX3X10s BATCH:DFE6337A DFE6338ADFE6339ADFE6340A | $50.0K | 1 |
| COLCIBRA CAP 200MG(CELECOXIB CAPSULES 200MG)PACK:BOX3X10S BATCH:DFE7088A | $50.0K | 1 |
| COLCIBRA CAPS 200MG PACK: 10s Strip BATCH: DFF6690A, DFF6793A EACH CAPSULES CONT.CELECOXIB CAPSULES EQ. TO 200 MG | $50.0K | 1 |
SUN Pharmaceutical Industries Limited exports 105 distinct Celecoxib formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CELECOXIB CAP 200MG 10S BRAZ PACK:10s ST with 4 shipments worth $122.5K.
Regulatory Requirements: Exporting Celecoxib to Key Markets
What SUN Pharmaceutical Industries Limited must comply with to export Celecoxib to its top destination countries
South Africa — SAHPRA
Approval Process
Registration under SAHPRA guidelines (CTD format). Bioequivalence required for generics.
Timeline: 24–48 months (significant backlog)
GMP & Export Requirements
WHO GMP or PIC/S GMP compliance
Certificate of Pharmaceutical Product from CDSCO; Import permit per Section 22A of Medicines Act
Note: Known registration backlog. WHO Prequalification significantly assists the process.
Brazil — ANVISA
Approval Process
Generic registration under RDC 200/2017. ANVISA GMP inspection of Indian facility mandatory before approval.
Timeline: 12–24 months
GMP & Export Requirements
ANVISA GMP certificate (CBPF) for each manufacturing site; on-site inspection by ANVISA
Certificate of Pharmaceutical Product from CDSCO; Import Authorization via SISCOMEX
Note: ANVISA maintains active Indian pharma facility inspection program. Inspection backlog can extend timelines.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does SUN Pharmaceutical Industries Limited Compare to Nearest Celecoxib Exporters?
Exporters ranked immediately above and below #11 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 9 | APOTEX RESEARCH PRIVATE LIMITED | $3.2M | 77 | 3 | $41.1K |
| 10 | STRIDES PHARMA SCIENCE LIMITED | $2.8M | 92 | 2 | $30.8K |
| 11 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ★ | $2.8M | 127 | 9 | $22.0K |
| 12 | EMCURE PHARMACEUTICALS LIMITED | $2.3M | 146 | 1 | $15.7K |
| 15 | GRACURE PHARMACEUTICALS LIMITED | $1.9M | 75 | 8 | $25.5K |
SUN Pharmaceutical Industries Limited ranks #11 among 326 Indian Celecoxib exporters. Average shipment value of $22.0K compared to the market average of $192.8K. The closest competitors by value are APOTEX RESEARCH PRIVATE LIMITED and STRIDES PHARMA SCIENCE LIMITED.
Which Indian Ports Ship Celecoxib Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 544 | 11.1% |
| DELHI AIR CARGO ACC (INDEL4) | 475 | 9.7% |
| SAHAR AIR CARGO ACC (INBOM4) | 433 | 8.9% |
| SAHAR AIR | 323 | 6.6% |
| JNPT/ NHAVA SHEVA SEA | 305 | 6.3% |
| DELHI AIR | 256 | 5.2% |
| JNPT | 216 | 4.4% |
| MUNDRA SEA | 196 | 4.0% |
Geopolitical & Trade Policy Impact on SUN Pharmaceutical Industries Limited's Celecoxib Exports
Sun Pharma's export operations, valued at $979.8 million, are significantly influenced by current geopolitical events. The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to Europe and North Africa. Major shipping lines have imposed 'Emergency Risk Surcharges,' increasing freight costs and extending transit times by 10–15 days. These delays pose risks to the integrity of time-sensitive and temperature-controlled pharmaceutical shipments. (pharmaceuticalcommerce.com)
In the United States, policy shifts towards domestic manufacturing and the imposition of tariffs on imported pharmaceuticals have created challenges for Indian exporters. Sun Pharma, which supplies a substantial portion of generics to the U.S. market, faces potential reductions in export volumes due to these protectionist measures. The company is exploring strategies such as establishing local partnerships and investing in U.S.-based manufacturing to mitigate these impacts. (odrindia.in)
The European Union's implementation of the Carbon Border Adjustment Mechanism (CBAM) introduces additional compliance requirements for exporters. Sun Pharma must adapt to these regulations to maintain its market presence in the EU, necessitating investments in sustainable manufacturing practices and comprehensive reporting mechanisms. (sgeexport.com)
SUN Pharmaceutical Industries Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards remains a critical focus for Sun Pharma. The company has encountered challenges with the U.S. FDA, including import alerts and non-compliance letters for certain facilities. Addressing these issues involves implementing corrective actions and awaiting reinspection to resume full operations. (business-standard.com)
Globally, the pharmaceutical industry faces increasing scrutiny regarding quality standards. Sun Pharma's commitment to adhering to Good Manufacturing Practices (GMP) and other regulatory requirements is essential to maintain its export licenses and market reputation. Continuous investment in quality control systems and compliance infrastructure is imperative to navigate the evolving regulatory landscape.
About SUN Pharmaceutical Industries Limited
SUN Pharmaceutical Industries Limited exports 118 products worth $979.8M. Beyond Celecoxib, top products include Strip, Esomeprazole, Magnesium, Calcium, Omeprazole. View the complete SUN Pharmaceutical Industries Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Celecoxib — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Celecoxib shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: SUN Pharmaceutical Industries Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 135 individual customs records matching SUN Pharmaceutical Industries Limited exporting Celecoxib, covering 105 formulations to 9 countries via 45 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 112+ countries, 781+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Celecoxib Export Data from SUN Pharmaceutical Industries Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for SUN Pharmaceutical Industries Limited's Celecoxib exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
SUN Pharmaceutical Industries Limited
Full Company Profile →
118 products · $979.8M total trade · 25 categories
Celecoxib Stats
Company Overview
Top Products by SUN Pharmaceutical Industries Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for SUN Pharmaceutical Industries Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Celecoxib. For current shipment-level data, contact TransData Nexus.